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Background: Around 20% of patients with acute pancreatitis (AP) will develop acute recurrent pancreatitis (ARP) 
and 10% will progress to chronic pancreatitis. While interventions to avoid recurrences exist for the two most 
common causes – abstinence for alcoholic and cholecystectomy for biliary pancreatitis – the are no known 
preventive measures in idiopathic ARP. Though it is not included in any of the guidelines, a low-fat diet is often 
recommended.  
Our aim is to test dietary fat reduction’s effect on AP recurrence in a randomized controlled setting, in order to 
provide high-quality evidence for the validity of such an intervention. 
Methods, design: Participants with at least 2 episodes of AP in the preceding 2 years of which the last episode 
was idiopathic will be randomized to one of two diets with different fat contents: a ‘reduced fat diet’ (15% fat, 
65% carbohydrate, 20% protein) and a ‘standard healthy diet’ (30% fat, 50% carbohydrate, 20% protein; based on 
WHO recommendations). Participants will be followed-up for 2 years (visits will be scheduled for months 3, 6, 
12, 18 and 24) during which they will receive a repeated session of nutritional guidance, complete food frequency 
questionnaires and data on relapse, mortality, BMI, cardiovascular parameters and serum lipid values will be 
collected.  
Discussion: This study will determine the effect of modifying the dietary fat content on AP recurrence, mortality, 
serum lipids and weight loss in idiopathic cases.  
Trial registration: The study is registered at clinicaltrials.gov under registration number NCT04761523 
Ethical approval number: 40304-11/2020/EÜIG 




Acute pancreatitis (AP) is an inflammatory disorder of the pancreas, most frequently caused by excessive alcohol 
consumption and gallstones 1. Around 20% of patients with AP will develop acute recurrent pancreatitis (ARP) 
and 10% progress to chronic pancreatitis (CP) 2. While interventions exist to avoid recurrences in the case of the 
two major etiologies – abstinence in alcoholic AP and cholecystectomy in biliary AP – there are no preventive 
therapeutic options for patients with idiopathic ARP. One possibility would be to comply with a low-fat diet, which 









Though it is indeed frequently recommended, maintaining a low-fat diet after AP is not included in any of the 
guidelines 3-5 and evidence is scarce. In a prospective cohort of more than 36,000 participants, Prizment et al. 
found increased total and saturated fat intake to be associated with AP 6. Setiawan et al. observed a positive 
association between saturated fat intake and gallstone-related AP, but not with non-gallstone-related AP, ARP or 
CP 7. Oskarsson et al. prospectively studied a cohort of non-gallstone-related AP patients with no clear associations 
between overall diet quality and pancreatitis recurrence or progression 8. Aside from the recognized connection 
between high fat intake and gallstone formation, thus biliary AP 9, 10, there are hypotheses as to why fat excess 
could be a risk factor for non-biliary pancreatitis as well. One possible reason can be the elevated serum triglyceride 
(TG) levels, a known etiological factor for AP, stimulating free fatty acid production which is believed to be 
pancreatotoxic 6, 11-13. Zhang et al. found that a chronic high-fat diet in rats increased levels of pancreatic free fatty 
acids and lipid peroxidation, associated with pancreatic injuries and collagen synthesis via activated pancreatic 
stellate cells 14. Animal experiments have also described a more severe AP course in animals on high-fat diets 15.  
While the aforementioned cohort trials boast an impressive number of participants the study design is not suitable 
to determine a cause-effect relationship between dietary fat content and pancreatitis recurrence. 
Our aim was to conduct a randomized controlled trial (RCT) comparing two low-fat diets that contain the same 
amount of calories and protein but have different fat contents (15 and 30% respectively) in order to determine the 
effect of dietary fat content reduction on AP recurrence. We wanted to include patients with idiopathic ARP as 
this is the group without a preventive therapeutic option. Our hypothesis is that while patients on both arms will 
benefit from receiving nutritional guidance, those with less fat in their diet will see an additional benefit due to the 




Trial design, study setting 
This study will be a multicenter, prospective, parallel-group RCT with a superiority framework. Participants will 
be randomly assigned in a 1:1 ratio to one of 2 different dietary interventions which are: a ’reduced fat diet’-arm 
and a ‘standard healthy diet’-arm (largely based on WHO recommendations) to be further detailed in the 
‘Interventions’-section of this protocol.  
The chief study site will be an academic hospital (1st Department of Medicine, Medical School, University of Pécs 












The inclusion and exclusion criteria for this trial are detailed in Table 1. A participant must meet all of the inclusion 
criteria and none of the exclusion criteria to be eligible for enrolment. 
 
Interventions 
Description of interventions 
Participants will be randomly assigned in a 1:1 ratio to one of 2 different dietary interventions which are as follows: 
(1) a ’reduced fat diet’ in which the daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% 
proteins; (2) a ‘standard healthy diet’ (which also qualifies as a low-fat diet and is largely based on WHO 
recommendations) in which the daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% 
proteins.  
Diets will be individualized to each participant. We will provide, for both arms, recommendations and meal-plans 
prepared every 200 kcals between 1800 and 3000 kcal. Before performing the dietary intervention, study dieticians 
will be required to use one of these sample diets and tailor it to the exact calorie needs of the participant (and if 
necessary, make alterations based on the country of the enrolling center). 
Consultations will take place in an outpatient setting. When assigned to an intervention, first, patients will complete 
a food frequency questionnaire (FFQ – the National Health and Nutrition Examination Survey FFQ) to assess their 
eating habits. Then, based on their assigned intervention group they will receive recommendations according to 
the given diet. These consultations will be conducted by study dieticians centrally trained and evaluated by a 
qualified dietician coordinator. Relatives of the participants will also be allowed to attend these consultations, 
since the cooperation and involvement of family members can augment adherence and it is possible that the 
participant is not personally involved with the alimentation of the household. 
The FFQ applied in this study is not only capable of assessing fat, carbohydrate and protein consumption but will 
provide a more detailed breakdown of dietary intake. Such detail is needed to account for other dietary variables 
possibly skewing data (not very likely due to randomization) and to conduct subgroup analyses – for details, see 










Participants will be advised to discontinue their allocated intervention (through personal communication or if 
impossible, other means – phone, e-mail, mail) if any of the following happens: 
(1) The participant withdraws his/her consent, (2) fails to attend two consecutive visits (3) develops one of the 
conditions mentioned in the exclusion criteria, or (4) completes the study. In these cases, participants will be 
advised to keep a balanced diet (according to WHO recommendations) with appropriate amount of calories to their 
age, gender, body weight and physical activity 16. 
Based on any positive results of our study, dietary recommendation for this patient population might change and 
testing the long-term effect of these diets on pancreatitis recurrence, progression to CP and mortality might become 
necessary in form of a separate controlled trial.  
 
Adherence 
Compliance with dietary interventions is often problematic, this was taken into account when estimating the 
required sample size. We will, however, attempt to augment adherence via a repeated dietary intervention at the 
second visit, by completing FFQs with participants with the explicit purpose of estimating adherence and by 
reminding participants that through the evaluation of their BMI, laboratory results and FFQs we will have a good 
overview on whether or not they complied with the recommendations. These data will also be used to give 
motivational feed-back to the participants at the second visit.  
Additionally, before participants consent to take part in the study they will be provided with detailed information 
on the composition and fiscal aspects of both diets so as to reduce drop-outs after-randomization. Our center will 
also maintain a “hotline” – a telephone number that can be reached during working hours to answer questions that 
emerged regarding the diet. 
 
Concomitant care 
Concomitant interventions that do not categorically alter the diet of participants will not be limited. 
 
Outcomes 
Primary outcome measures 
The primary outcome measure for this trial will be (1) a composite endpoint: the recurrence of AP (given as a rate 










Secondary outcome measures 
Secondary outcome measures will be the following: (1) Pancreas-specific mortality; (2) Cardiovascular cause 
mortality, (3) newly diagnosed CP, (4) changes in BMI compared to baseline (both total and percentage), serum 
lipid parameters (values and change from baseline), including: (5) total cholesterol, (6) TG, (7) HDL-cholesterol 
and (8) LDL-cholesterol; (9) serum albumin value and change from baseline, levels of (10-13) vitamins A, D, E 
and K (value and change from baseline); (14) blood pressure (systolic and diastolic) values and change compared 
to baseline. We will also assess (15) current smoking at the time of each visit, (16) adherence to dietary 
recommendations (as determined by the results of a food frequency questionnaire); (17) adverse events (given as 
rate of events). We will also assess (18) quality of life with the EQ-5D-5L questionnaire (see in supplementary 
material) and (19) muscle strength using a handgrip dynamometer (value and change from baseline for both). 
 
Additional data collected at baseline 
The index visit will entail an additional patient questionnaire and retrospective chart review collecting data on: 
comorbidities (diabetes, hypertension, chronic heart disease, chronic kidney disease, chronic liver disease, stroke, 
etc.), socioeconomic status (education, occupation, income, subjective social status) and past pancreatic history: 
how many episodes of AP, etiology of former episodes, is CP present. In case the patient has a new episode of AP 
during the study period, its etiology will also be recorded.  
Data collection forms are available in our supplementary material.  
 
Biologic sample collection  
At enrollment and every visit, basic laboratory tests from blood will be carried out and participants will provide 
blood for storage in the biobank.  
Laboratory parameters measured are shown on the data collection forms in our supplementary material. In case of 
alarming laboratory results, a physician will be notified, who will decide whether further medical attention is 
necessary. All patients will receive the results of their laboratory tests in written form.  
The samples in the biobank will be stored at −80°C and identified by the personal identification number (PIN) 
given at study entry. All samples will be collected and sent together to the laboratory when the patient number 









From the collected biological samples, we will – for not diagnostic, but research purposes – conduct genetic 
analyses. In case the result of these analyses contains information that impacts the health of either the participant 
or their relatives, we will inform them via one of the provided methods of availability.  
 
Participant timeline 
All participants will appear at the study site according to the study schedule (Table 2).  
To determine eligibility, physical examination, BMI measurement, laboratory testing and a review of the 
individuals’ medical history and documentation in order to rule out AP with an established etiology will be 
performed. At the time of allocation and before receival of the intervention baseline values for outcomes (4-15, 
18, 19) will be collected and participants will be physically examined as well as a FFQ will be completed with the 
help of a study administrator, all in an outpatient setting. All outcomes will be assessed at 3, 6, 12, 18 and 24 
month visits. Participants will receive a repeated dietary intervention at months 3, 6, 12 and 18. 
 
Sample size 
As there are no similar studies to date, we will employ a two-stage trial design – we estimated a likely accurate 
participant number of 384 accounting for drop-outs, equally allocated (192-192) to both intervention groups which 
we will refine according to the results of an interim analysis performed at the time of reaching 50% (n=192) of the 
planned participant number. We based this preliminary estimate on (1) recurrence rates among patients with at 
least 2 episodes of AP within 2 years from the Hungarian Pancreatic Study Group’s (HPSG) AP registry and (2) 




Recruitment will be performed in 2 distinct ways: (1) patients can be asked to participate during their pancreatitis-
associated hospital stay, or (2) eligible patients identified through medical database search can be contacted with 
a proposal of participation. The planned start of recruitment is 2021.07.01. with a proposed end of 2026.07.01. 
 
Assignment of interventions 









Central randomization will be used with randomly permuted block size and allocation ratio of 1:1 using a 
computer-generated random sequence. Participants will be stratified based on (1) the presence of CP and (2) the 
presence of DM. Inclusion criteria and exclusion criteria will be checked prior to computer-aided randomization 
via an online platform to ensure that only eligible patients are included in the trial. The platform generates a PIN. 
The computer-aided randomization ensures allocation concealment. The randomization procedure will be 
performed by the same person who screened and consented the patient. 
 
Blinding 
Due to their role in delivering the individualized dietary intervention, study dieticians cannot be blinded to the 
group of the participants. Since they complete the FFQs with the participants, the assessment of dietary habits will 
not be blinded. Doctors caring for the participants and assessors of all other outcomes (laboratory parameters, 
BMI, blood pressure, adverse events) as well as statisticians handling the data will be blinded to the participants’ 
allocated group. Participants will also be blinded – they will be informed of the trial structure and that they will be 
randomized to one of two diets with different dietary fat contents but they will be warned in advance that dieticians 
will not reveal to them whether they are in the ‘reduced fat diet’ arm or the ‘standard healthy diet’ arm. Naturally, 
they will be informed and allowed to ask in detail regarding the composition of these two diets, but it is our firm 
belief, that based only on this information and the meal-plan that the dietician will give to the participants, the vast 
majority will not know which arm they are on.  
 
Data management, analysis and monitoring 
Data management and monitoring 
Investigators will be responsible for the accuracy, reliability and quality of the collected data. Detailed data flow 
will be described in a Data Management Plan. Data from completed electronic case report forms (eCRFs) will be 
validated under the direction of the Data Manager on the DMC according to a Data Cleaning Plan. Any missing, 
implausible, or inconsistent recordings in the eCRFs will be referred back to the Investigator using a data query 
form and will be documented for each subject before clean file status is declared. All changes to eCRFs will be 
recorded.  
The DMC will perform an independent assessment of trial-related documents and activities to ensure respect for 
subjects’ rights, safety and well-being and to guarantee the plausibility of clinical data. The similarity of groups at 









After written consent of the subjects, data will be recorded by the investigators. Clinical research data will be 
processed separately from participants’ personal data. Data may only be accessed by persons acting under the 
authority of the controller and in accordance with the authorization system established within the controller’s 
organizational structure, only to the extent and in the manner necessary for the performance of tasks. Personal data 
will not be made accessible to third parties. 
 
Statistical analysis plan 
In the final analysis, the intention-to-treat analysis will be favored over per-protocol (or "as-treated”) analysis. We 
expect there will be no missing data for the primary outcome. In case there is, we will use available case analysis. 
The “last observation carried forward” strategy will be followed to impute missing data for other outcomes 
measured during the study, including data from the National Health Insurance Fund (or similar organizations in 
case of foreign centers). 
In descriptive statistics, the count and percentage will be provided for each treatment arm for binary outcomes. 
For continuous outcomes, n, mean, median, interquartile (Q3–Q1), standard deviation, minimum, and maximum 
values will be provided for each treatment arm. In a univariate comparative analysis, we will calculate relative risk 
with 95% confidence interval (CI) when comparing the primary endpoint between two groups (alpha=5%) with a 
reference arm using non-repeated intervention complemented with chi-square or Fisher’s exact test (the same 
strategy will be followed for binary secondary outcomes). For continuous variables, we will use t-test assuming 
unequal variances or the Mann-Whitney test. We will perform univariate (Kaplan-Meier and Cox-regression) and 
multivariate (Cox-regression) survival analysis for binary outcomes. An adjustment will be carried out at least for 
age, sex, BMI, smoking and education.  
Results derived from the FFQs of the patients will give ground for subgroup analyses based on dietary factors. 
Pre-planned subgroup analyses will be based on: dietary adherence, alcohol consumption, daily calorie intake, true 
fat consumption, unsaturated and saturated fat consumption, trans-fat consumption and processed food 
consumption. We are also planning to conduct subgroup analyses based on the presence of known genetic variants 
in AP.  
All analyses will be carried out with SPSS version 26 and Stata version 15. 
 









The corresponding center of the EFFORT study is the Centre for Translational Medicine at the University of Pécs 
Medical School (www.tm-centre.org), whereas the coordinator and designer research team is the HPSG 
(https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/). The HPSG has been running high-
quality international, multicentre clinical trials since 2014 18-21 and has published relevant guidelines for pancreatic 
diseases to improve patient care in pancreatology 22, 23.  
The Steering Committee (SC) will be led by PH (principal investigator, gastroenterologist, specialist in internal 
medicine and clinical pharmacology). SC members will be MFJ (study coordinator), NF (biostatistician); ZsV 
(dietician coordinator); FI, LCza, MP, AP (center representatives). There will be independent members as well, 
and the SC will include a patient representative. The SC will supervise the trial primarily and will make decisions 
regarding all critical questions (e.g., premature termination of the study, dropouts, etc.). 
All data gathered for research purposes will be handled confidentially and anonymously, which will be ensured 
by the Data Monitoring Committee (DMC). For each participant, a PIN will be generated that will be present on 
all forms and documents of each individual. 
The International Advisory Board (ITAB) will include MW, SJP, FJ and GC. 
The study was designed by the SC and was supported by the University of Pécs, Medical School. The sponsor had 
no role in the design of the trial and will have no access to the randomization codes or the data. 
Five eligible patients were invited to review the protocol and to discuss any concerns or doubts that emerged. 
Remarks made during this meeting were incorporated into the final version of the protocol. The participant 
prospects positively responded to the concept of the study and highlighted its importance, agreed that the primary 
outcome was crucial. They deemed the forms and questionnaires understandable and appropriate. We originally 
planned only 2 follow-ups at months 12 and 24, but upon discussing it with the participant prospects they 
highlighted the importance of frequent controls in supporting dietary adherence, thus we modified the study 
schedule to include more visits. We also added the option of calling for dietary advice and for relatives to attend 
the dietary consultation to augment adherence, as described in the ‘Adherence’ and ‘Description of interventions’ 
sections of the protocol. The participant prospects described no negative feelings or ethical concerns regarding 
blood sample tests and the two interventions used in the study.  











(1) Upon reaching 10% of the target sample size an interim safety analysis will be performed wherein the Safety 
Monitoring Board will review data of the patients and determine whether the occurrence of any negative effects 
can be linked to any of the interventions and if needed the given intervention or the trial will be terminated for the 
safety of the patients. 
At the point of the safety analysis, patient data will only be made available to the Safety Monitoring Board and 
they will make the final decision whether or not to terminate the trial. 
(2) Upon reaching 50% of the target sample size an interim analysis will be performed in order the refine the 
number of participants necessary to complete the trial (see ‘Sample size’). 
 
Safety 
As our primary interest was the safety of participants, we did not overstep the WHO recommended maximum 30% 
fat intake (which already qualifies as a low-fat diet) just to better observe differences in AP recurrence. Maintaining 
such a balanced diet or a diet with an added reduction in fat content similar to what we aim to assess poses no 
health risks whatsoever. Adverse events in these cases might be due to a formerly excessive eater attempting 
controlled intake, such as irritation, fatigue, maybe headache. Other minor and moderate events may occur, but 
we expect no serious side effects with either of the interventions. In case a potentially serious health problem is 
detected by the investigators related to the intervention, the Safety Monitoring Board will be notified. To avoid 
detection bias in assessing adverse events doctors conducting patient examination will be advised to ask all patients 
about the presence of nausea, abdominal pain and changes in stool.   
The frequent dietary monitoring will also allow for the prompt recognition and treatment of malnourished 
participants.  
Upon reaching 10% of the target sample size an interim safety analysis will be performed wherein the Safety 
Monitoring Board will review data of the patients and determine whether the occurrence of any negative effects 
can be linked to any of the interventions and if needed the given intervention or the trial will be terminated for the 
safety of the patients. 
 
Ethics, dissemination 
This trial is registered on clinicaltrials.gov (NCT04761523). 
This study was approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research 









Planned start of patient recruitment: 2021.07.01. 
Anticipated study duration: 5-6 years. 
Study results will be published in an international scientific journal. Study sponsors have no role in writing the 
publication, deciding to publish and choosing the target journal. 
 
Protocol amendments 
In case of any changes and deviations from the original protocol, investigators and past participants will be 
contacted via email, letter, or phone; future participants will be notified in person during inclusion; deviations 
from the original protocol will be indicated on clinicaltrials.gov and in any and all publications originating from 
the acquired data.  
 
Consent  
Informed consent for participation in the study and providing biological samples will be collected by medical 
doctors. For a model adult consent form see our supplementary material. Consent forms are tailored to the age of 




It has been a long-standing conviction that dietary fat content, even in the absence of immoderate calorie intake 
and putting biliary factors aside, can influence pancreatic pathogenesis. This study is the first to test this hypothesis 
in a randomized, controlled setting.  
The results of our study will determine the effect of modifying the dietary fat content on AP recurrence, mortality, 
serum lipids and weight loss in idiopathic ARP cases ie. the patient group in which there is a dire need for 
interventions to positively influence the course and progression of the disease.  
 
Strengths and limitations 
The main strength of this study is that it is the first RCT to test the effect of dietary fat content on pancreatitis 
recurrence, thus providing high quality evidence for one of the central questions of pancreatology.  
Limitations: As we tried to counteract the expected low event rate and finer differences between interventions with 









This could be ameliorated by multiple centers joining and supplying eligible participants already in their care. 
While it will provide insight on the effect of dietary fat content on recurrence, this comparison in itself is unsuitable 
to determine the effect of a low-fat diet compared to not dieting / excessive eating. We did not include such an 
arm as we found it unethical to not provide an individual with dietary recommendations after AP. However, we 
plan to estimate this effect, by comparing the groups with the best and worst dietary adherence based on the result 
of FFQs.  
 
Implication for research: ketogenic diet 
Originally, we planned to include a 3rd arm in our trial: a ketogenic diet arm. Several meta-analyses of RCTs 
compare such a diet to a low-fat diet in healthy individuals, or patients with malignancies, observing a favorable 
effect on diastolic blood pressure (DBP), serum TG and HDL-cholesterol levels 24-27. However, issues regarding 
feasibility emerged. A ketogenic diet arm would have significantly raised the required patient number while 
introducing additional exclusion criteria to an already select patient population. Interview of participant prospects 
(see ‘Roles and responsibilities) also revealed a low willingness to adhere with this diet. However, we encourage 




Center costs (IT, biostatistics, trial organization etc.) are covered by the University of Pécs, Medical School, other 
costs are funded by „GINOP-2.3.2-15-2016-00048 - STAY ALIVE” co-financed by the European Union 
(European Regional Development Fund) within the framework of Programme Széchenyi 2020, and by Human 
Resources Development Operational Programme Grant, Grant Number: EFOP 3.6.2‐ 16‐ 2017‐ 00006 – LIVE 
LONGER  which is co-financed by the European Union (European Regional Development Fund) within the 
framework of Programme Széchenyi 2020 as well as the Translational Medicine Foundation. MFJ received a New 
National Excellence Programme (ÚNKP) grant. AP received the János Bolyai Research Scholarship of the 
Hungarian Academy of Sciences. The study sponsors were not involved in the design of the study and will have 
no access to database or the randomization code. 
There are no financial or other competing interests among the principal investigator, the included participants or 











Authorship was determined according to International Committee of Medical Journal Editors (ICMJE) 
recommendations. All authors participated in either drafting the study or providing critical revisions; all authors 
have read and approved the final manuscript version and are in agreement to be accountable for all aspects of the 
work. 
Apart from above mentioned responsibilities, MFJ, KO, LS, NF, ZS, NZ, AP and PH made substantial 
contributions to the concept and design of the trial. Data collection was carried out by MFJ. NF performed the 
sample size estimation, based on data provided by MFJ and AP. MFJ wrote the majority of the manuscript. LCzo 
will also act as an independent Safety Monitor for the study. MW, SJP, FJ, GC, PGA, FI, LCza, MP, AP and PH 
will play a key role in participant enrolment and data acquisition. Every involved center can name coauthors for 
later publications for every 15 enrolled participant. Further roles are detailed in the ‘Trial organization, committees 
and boards’ section of the protocol. 
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Table 1 – Inclusion and exclusion criteria. One unit of alcohol equals 10 ml or 8 g of pure alcohol. HbA1c: 




1. Individuals with at least two episodes of acute pancreatitis in the 2 years preceding the inclusion with 
2. The last episode being idiopathic, who are 
3. At least 14 years old. 
 
Exclusion criteria 
1. Individuals already receiving regular nutritional guidance (with medical indication), 
2. Individuals in critical condition or in terminal stage of cancer (with an expected survival <2 years) , 
3. Individuals undergoing treatment for active malignancy, 
4. Individuals with known cholecystolithiasis, 
5. Individuals with uncontrolled diabetes mellitus (admitted lack of compliance with antidiabetic therapy / 
HbA1c ≥7% / indication of uncontrolled diabetes mellitus in last 24 months’ anamnesis / newly discovered 
diabetes mellitus)  
6. Individuals who are pregnant or nursing 
7. Individuals with a BMI < 18.5  
8. Individuals who are regularly receiving systemic corticosteroids 
9. Individuals consuming more alcohol than: 5 units per day or 15 units per week for men; 4 units per day or 8 














Visit 2 Visit 3 Visit 4 Visit 5 Close-out 
-4 – 0 weeks 0 week 3 months 6 months 12 months 18 months 24 months 
ENROLMENT:        
Eligibility screen X       
Informed consent X       
Allocation  X      
INTERVENTIONS 
(dietary consultation) 
       
Reduced-fat group  X X X X X  
WHO-diet group  X X X X X  
ASSESSMENTS:        
Physical examination X X X X X X X 
BP, HR measurement  X X X X X X 
BMI measurement X X X X X X X 
Laboratory testing X X X X X X X 
Handgrip test  X X X X X X 
Food Frequency 
Questionnaire 
 X X X X X X 




 X      
Table 2 – SPIRIT schedule outlining timing of interventions and assessments. WHO: World Health 
Organization; BP: blood pressure; HR: heart rate; BMI: body mass index 
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